Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

January 2020

Efectos de Upadacitinib en los Resultados Reportados por los Pacientes: Resultados de SELECT-BEYOND, un Estudio clínico Aleatorizado de Fase 3 en Pacientes con Artritis Reumatoide y Respuesta Inadecuada a los Fármacos Antirreumáticos Modificadores de la Enfermedad

Arthritis Res Ther . 2019 Dec 2;21(1):263. doi: 10.1186/s13075-019-2059-8.

Song Y,

In SELECT-BEYOND, UPA demonstrated clinically meaningful improvements in patient reported outcomes compared to PBO in patients with RA who had an inadequate response to bDMARDs. In this post-hoc analysis of the SELECT-BEYOND study, the effect of UPA 15 or 30 mg on patient reported outcomes were assessed and compared to PBO.Eligible patients (498) with an inadequate response to bDMARDs were randomly assigned 1:1:1 to receive UPA 15 mg, UPA 30 mg or PBO. PROs collected at Wk1, Wk4, and Wk12 includ...

Keywords:

Upadacitinib Mejora los Resultados Reportados por los Pacientes en Pacientes con Artritis Reumatoide y Respuesta Inadecuada a Fármacos Antirreumáticos Modificadores de la Enfermedad Sintéticos Convencionales: Resultados de SELECT-NEXT

Arthritis Res Ther . 2019 Dec 9;21(1):272.

Pope J,

Camp H,

In SELECT-NEXT, UPA demonstrated clinically meaningful improvements in patient reported outcomes compared to PBO in patients with RA who had an inadequate response to csDMARDs. In this post hoc analysis, the effect of UPA 15 or 30 mg on patient reported outcomes were assessed and compared to PBO.Eligible patients (661) with an inadequate response to csDMARDs were randomly assigned 2:2:1:1 to receive background csDMARD therapy with either UPA 15 mg, UPA 30 mg or PBO. PROs collected at Wk4 and Wk1...